STAGES OF DEVELOPMENT

Innovation Pharma owns rights to Brilacidin, a de novo-designed defensin-mimetic drug candidate exhibiting anti-inflammatory and antimicrobial properties. Brilacidin has been evaluated in multiple clinical trials (over 500 patients treated to date), received special FDA designations and can be administered via various modes of delivery.